EJHaem · 2026
BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al Haddad Nadia, Brailovski Eugene, Dela-Pena Jacqueline, Cook Melinda, Rosenzweig Michael, Jolie Landau Heather
Аннотация
INTRODUCTION: Lambda immunoglobulin light chain (AL) amyloidosis associated with non-IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited.
METHODS: Here we describe the case of a patient with a history of LPL-associated AL amyloidosis who had previously been treated with multiple B-cell- and plasma-cell-directed regimens. At the time of relapse, pathology demonstrated plasmacytic histology, with BCMA-expressing plasma cells by immunohistochemistry and no detectable B-cell infiltrate. The patient subsequently received investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy.
RESULTS: Following BCMA-directed CAR T-cell therapy, the patient achieved a complete hematologic response.
CONCLUSION: This case highlights the biologic complexity of LPL-associated AL amyloidosis and supports the use of BCMA-targeted therapy, especially when the relapsing or residual disease is comprised by the plasma cell component.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06097832.
METHODS: Here we describe the case of a patient with a history of LPL-associated AL amyloidosis who had previously been treated with multiple B-cell- and plasma-cell-directed regimens. At the time of relapse, pathology demonstrated plasmacytic histology, with BCMA-expressing plasma cells by immunohistochemistry and no detectable B-cell infiltrate. The patient subsequently received investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy.
RESULTS: Following BCMA-directed CAR T-cell therapy, the patient achieved a complete hematologic response.
CONCLUSION: This case highlights the biologic complexity of LPL-associated AL amyloidosis and supports the use of BCMA-targeted therapy, especially when the relapsing or residual disease is comprised by the plasma cell component.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06097832.